Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultevursen in Retinitis Pigmentosa Due to USH2A Exon 13 Mutations
2024-515199-10-00Phase 2Withdrawn
- Sponsor
- Laboratoires Théa
- Start
- Mar 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) (2 arms), sponsored by Laboratoires Théa. Planned start Mar 2025; status: withdrawn.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-515199-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515199-10-00.